Weight Watchers has introduced a new subscription pricing model for Wegovy, a GLP-1 weight management medication, offering eligible Med+ members savings of up to $1,200 per year. This expanded collaboration with Novo Nordisk provides discounted monthly rates for pre-paid three, six, or twelve-month supplies, making FDA-approved obesity treatment more affordable and accessible. The program combines medication with Weight Watchers' lifestyle support, which has shown to improve weight loss outcomes. This move reflects growing demand for integrated weight health solutions and aims to sustain long-term results for members.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
